- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Chelsee Jensen Explains Implementing Biosimilars in Small vs Large Practices
Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.
Transcript
How does implementing tools for increasing biosimilar use differ between smaller and larger practices?
So, at a smaller practice site where maybe you're operating only in 1 state or maybe you just have a few commercial payers, or even if a majority of your payer mix is government payers, you can probably adopt biosimilars in a full fledge swoop. So, all at once vs our approach, which has been a phased approach of initiating new patients on biosimilars and then choosing a biosimilar at prior authorization renewal. So, if you're in a smaller health system, and you're able to pick a preferred product—because, again, maybe your payer landscape is more standardized—then you can have one set implementation date, have reduced inventory burden, and just improve workflows going forward.
Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities
November 19th 2024Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
